Skip to main navigation Skip to search Skip to main content

Long-Term Outcomes of Expectant Management versus Early Ibuprofen for Patent Ductus Arteriosus: 24-Month Follow-Up of the BeNeDuctus Trial

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

OBJECTIVE: To assess survival and neurodevelopmental outcomes at 24 months' corrected age in participants of the BeNeDuctus trial, comparing expectant management with early ibuprofen treatment in extremely preterm infants.

STUDY DESIGN: In this international, multicenter trial, extremely preterm infants (<28 weeks' gestation) with echocardiographically confirmed patent ductus arteriosus between 24 and 72 hours of postnatal age were randomly assigned to expectant management or early ibuprofen treatment. Follow-up was scheduled at 24 months' corrected age. The primary end point of this follow-up study was survival without neurodevelopmental impairment (NDI; Bayley Scales of Infant and Toddler Development III score of ≥85 in both the cognitive and motor domains). Additional outcomes included biometry, abnormal neurologic examination, and vision or hearing impairment.

RESULTS: Follow-up data were available for 234 of 273 patients (85.7%), with 117 patients in each study arm. Assessment of the primary end point was available for 200 of 234 patients (85.5%). Survival without NDI did not differ between groups, with 51 of 104 patients (49%) in the expectant management group and 47 of 96 (49%) in the early ibuprofen treatment group (relative risk, 1.00; 95% CI, 0.76-1.33). No significant differences were observed in the additional follow-up outcomes.

CONCLUSIONS: No difference was observed in survival without NDI at 24 months' corrected age between the expectant management and early ibuprofen treatment groups in the BeNeDuctus study sample. These results suggest no advantage of routine early ibuprofen treatment for survival and neurodevelopmental outcomes.

TRIAL REGISTRATION: ClinicalTrials.gov number, NCT02884219; EudraCT number, 2017-001376-28.

Original languageEnglish
Article number115292
JournalThe Journal of Pediatrics
Volume299
Early online date17 Sept 2026
DOIs
Publication statusE-pub ahead of print - 17 Sept 2026

Fingerprint

Dive into the research topics of 'Long-Term Outcomes of Expectant Management versus Early Ibuprofen for Patent Ductus Arteriosus: 24-Month Follow-Up of the BeNeDuctus Trial'. Together they form a unique fingerprint.

Cite this